CHM

6.25%

1.7¢ chimeric therapeutics limited

Ann: Positive in vitro data for CHM 1301 CAR NK cells, page-76

First 76 Last

Share
Profile

Follow
slick

14,237 Posts.

7557

24/11/23

18:54

Post #: 71096965
Share

Originally posted by dalts66: ↑

Agreed. The market knows best. And at the moment it hates risk.

A lot of the selling into the 4c zone has been holders with an average of somewhere between 12c and 35c selling to rebuy at 2.8c. This has created the sell pressure. But, with several days of higher than normal volume, they have been finding buyers. So we have a new base in the 3cish zone.

That sell pressure will dry up today, as T+2 and bpay wait makes today the last day to take advantage of the 2.8c buy back.

If volume return to its very low historical value, the price will drift up and down on small sell and buy orders. But if we get the right announcement to keep interest, it will drift up. But very hard to predict when volume historically is so low.

For me, I have taken a large position which will be averaged in the low 3c region now, and will hold until we hear more from the expansion trial into GBM.

Risks at the moment are that this raise fails in a large way. Or that the drugs dont keep performing as they should.

Mitigation for the finds if the raise fails, is delaying the new trial from hitting arms. Not ideal, but concentration of funds into GBM approval would be best for the company.
Data so far seems to point to the drugs working a treat.

So a rocky path ahead, but potential from this market cap is large.

Expand

Oooooooowww that’s a great way to describe current markets Dalta

“The market knows best. And at the moment it hates risk”

Hope you don’t mind if I use that one.

Cheers.

CHM Price at posting: 3.1¢ Sentiment: None Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

HLX

Helix investor makes partial takeover bid, proposing board changes

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

There are more pages in this discussion • 4 more messages in this thread...

First 76 Last

Add CHM (ASX) to my watchlist

(20min delay)
Last 1.7¢		Change 0.001(6.25%)		Mkt cap ! $15.07M

Open	High	Low	Value	Volume
1.7¢	1.9¢	1.7¢	$45.06K	2.512M

Buyers (Bids)

No.	Vol.	Price($)
1	62187	1.7¢

Sellers (Offers)

Price($)	Vol.	No.
1.8¢	200000	1

View Market Depth

No.	Vol.	Price($)
1	62187	0.017
17	2833886	0.016
19	2586784	0.015
3	708475	0.014
2	222223	0.013

Price($)	Vol.	No.
0.018	200000	1
0.019	1896071	5
0.020	1523093	7
0.021	290857	3
0.022	600000	2

Last trade - 16.10pm 30/08/2024 (20 minute delay)

CHM (ASX) Chart

Ann: Positive in vitro data for CHM 1301 CAR NK cells, page-76

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Helix investor makes partial takeover bid, proposing board changes

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Lendlease sells off US east coast construction operations in latest global divestment push

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Positive in vitro data for CHM 1301 CAR NK cells, page-76

Top Stories

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Helix investor makes partial takeover bid, proposing board changes

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Lendlease sells off US east coast construction operations in latest global divestment push

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News